BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

549 related articles for article (PubMed ID: 26872616)

  • 21. Clinico-morphological analysis of the neuroendocrine neoplasms of the gastroenteropancreatic system.
    Delektorskaya VV; Kozlov NA; Chemeris GY
    Klin Lab Diagn; 2013 Oct; (10):48-50, 10-3. PubMed ID: 24640093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuroendocrine tumor disease: an evolving landscape.
    Frilling A; Akerström G; Falconi M; Pavel M; Ramos J; Kidd M; Modlin IM
    Endocr Relat Cancer; 2012 Oct; 19(5):R163-85. PubMed ID: 22645227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters.
    Niederle MB; Hackl M; Kaserer K; Niederle B
    Endocr Relat Cancer; 2010 Dec; 17(4):909-18. PubMed ID: 20702725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution.
    Massironi S; Rossi RE; Casazza G; Conte D; Ciafardini C; Galeazzi M; Peracchi M
    Neuroendocrinology; 2014; 100(2-3):240-9. PubMed ID: 25428270
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinicopathological heterogeneity between primary and metastatic sites of gastroenteropancreatic neuroendocrine neoplasm.
    Shi H; Jiang C; Zhang Q; Qi C; Yao H; Lin R
    Diagn Pathol; 2020 Sep; 15(1):108. PubMed ID: 32917216
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endocrine paraneoplastic syndromes in patients with neuroendocrine neoplasms.
    Daskalakis K; Chatzelis E; Tsoli M; Papadopoulou-Marketou N; Dimitriadis GK; Tsolakis AV; Kaltsas G
    Endocrine; 2019 May; 64(2):384-392. PubMed ID: 30280284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Consensus and controversy on subtype classification of gastric neuroendocrine neoplasms].
    Tan H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):977-981. PubMed ID: 28900986
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pattern and risk factors for distant metastases in gastrointestinal neuroendocrine neoplasms: a population-based study.
    Cai W; Tan Y; Ge W; Ding K; Hu H
    Cancer Med; 2018 Jun; 7(6):2699-2709. PubMed ID: 29733523
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Value of Somatostatin Receptor Scintigraphy (SRS) in Patients with NETG1/G2 Pancreatic Neuroendocrine Neoplasms (p-NENs).
    Kolasińska-Ćwikła AD; Konsek SJ; Buscombe JR; Maciejkiewicz K; Cichocki A; Roszkowska-Purska K; Sawicki Ł; Tenderenda M; Cwikla JB
    Nucl Med Rev Cent East Eur; 2019; 22(1):1-7. PubMed ID: 30276787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation of World Health Organization 2010 Classification for Gastroenteropancreatic Neuroendocrine Neoplasms with the Prognosis of Ovarian Neuroendocrine Neoplasms: Kansai Clinical Oncology Group-Protocol Review Committee/Intergroup Study.
    Kai K; Nasu K; Nishida H; Daa T; Shikama A; Shiozaki T; Kurakazu M; Yano M; Imamura Y; Tokunaga H; Tasaki K; Iida Y; Yamada Y; Morisawa H; Nakagawa S; Fujimoto E; Tsuruta T; Matsumoto H; Arakawa A; Nonaka M; Takano H; Ushiwaka T; Mori T; Ito K; Motohashi T; Teramoto N; Yamada T
    Neuroendocrinology; 2021; 111(4):320-329. PubMed ID: 32097950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a three-centric case-control study.
    Feola T; Puliani G; Sesti F; Modica R; Centello R; Minotta R; Cannavale G; Di Meglio S; Di Vito V; Lauretta R; Appetecchia M; Colao A; Lenzi A; Isidori AM; Faggiano A; Giannetta E
    J Endocrinol Invest; 2022 Apr; 45(4):849-857. PubMed ID: 35040099
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic factors of patients with gastroenteropancreatic neuroendocrine neoplasms.
    Huang PY; Tsai KL; Liang CM; Tai WC; Rau KM; Wu KL; Huang CC; Chuah SK
    Kaohsiung J Med Sci; 2018 Nov; 34(11):650-656. PubMed ID: 30392572
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
    ; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
    Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is determination of matrix metalloproteinases and their tissue inhibitors serum concentrations useful in patients with gastroenteropancreatic and bronchopulmonary neuroendocrine neoplasms?
    Blicharz-Dorniak J; Kos-Kudła B; Foltyn W; Kajdaniuk D; Marek B; Zemczak A; Strzelczyk J
    Endokrynol Pol; 2012; 63(6):470-6. PubMed ID: 23339005
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidemiologic trends and survival of early-onset gastroenteropancreatic neuroendocrine neoplasms.
    Yao H; Hu G; Jiang C; Fan M; Yuan L; Shi H; Lin R
    Front Endocrinol (Lausanne); 2023; 14():1241724. PubMed ID: 37701903
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunohistochemical Study of Mitosis-regulatory Proteins in Gastroenteropancreatic Neuroendocrine Neoplasms.
    Briest F; Wang Y; Arsenic R; Elezkurtaj S; Berg E; Greshake S; Lock AC; Hörsch D; Arnold CN; Hummel M; Siegmund B; Grabowski P
    Anticancer Res; 2018 Jul; 38(7):3863-3870. PubMed ID: 29970506
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complications of surgery for gastro-entero-pancreatic neuroendocrine neoplasias.
    Albers MB; Almquist M; Bergenfelz A; Nordenström E
    Langenbecks Arch Surg; 2020 Mar; 405(2):137-143. PubMed ID: 32291468
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading.
    Cavalcanti E; Armentano R; Valentini AM; Chieppa M; Caruso ML
    Cell Death Dis; 2017 Aug; 8(8):e3004. PubMed ID: 28837143
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs).
    Puccini A; Poorman K; Salem ME; Soldato D; Seeber A; Goldberg RM; Shields AF; Xiu J; Battaglin F; Berger MD; Tokunaga R; Naseem M; Barzi A; Iqbal S; Zhang W; Soni S; Hwang JJ; Philip PA; Sciallero S; Korn WM; Marshall JL; Lenz HJ
    Clin Cancer Res; 2020 Nov; 26(22):5943-5951. PubMed ID: 32883742
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New insights in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.
    Yin F; Wu ZH; Lai JP
    World J Gastroenterol; 2022 May; 28(17):1751-1767. PubMed ID: 35633912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.